Wordt geladen...
克唑替尼治疗晚期或复发性ALK阳性非小细胞肺癌的疗效和安全性
BACKGROUND AND OBJECTIVE: Anaplastic lymphoma kinase (ALK) positive in non-small cell lung cancer (NSCLC) was about 5%-7% and ALK tyrosine kinase inhibitor (TKI) was the standard treatment in NSCLC. The aim of this study is to evaluate the efficacy and safety of crizotinib in patients with advanced...
Bewaard in:
| Gepubliceerd in: | Zhongguo Fei Ai Za Zhi |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
中国肺癌杂志编辑部
2019
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6717874/ https://ncbi.nlm.nih.gov/pubmed/31451138 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2019.08.02 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|